TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
September 29 2020 - 8:00AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage
immunotherapy company with a pipeline of novel T cell therapies for
patients suffering from cancer, today announced that management
will participate in a fireside chat at the Jefferies Cell Therapy
Virtual Summit on Monday, October 5, 2020 at 2:00pm E.T. using a
virtual platform.
A live webcast of the presentation will be
available on the Investors page of the Company’s website at
https://investors.tcr2.com. An archived replay will be available
for at least 30 days following the presentation.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage immunotherapy company developing a pipeline of novel
T cell therapies for patients suffering from solid tumors or
hematological malignancies. TCR2’s proprietary T cell
receptor (TCR) Fusion Construct T cells (TRuC®-T cells)
specifically recognize and kill cancer cells by harnessing
signaling from the entire TCR, independent of human leukocyte
antigens (HLA). In preclinical studies, TRuC-T cells have
demonstrated superior anti-tumor activity compared to chimeric
antigen receptor T cells (CAR-T cells), while secreting lower
levels of cytokine release. The Company’s lead TRuC-T cell product
candidate targeting solid tumors, TC-210, is currently being
studied in a Phase 1/2 clinical trial to treat patients with
mesothelin-positive non-small cell lung cancer (NSCLC), ovarian
cancer, malignant pleural/peritoneal mesothelioma, and
cholangiocarcinoma. The Company’s lead TRuC-T cell product
candidate targeting hematological malignancies, TC-110, is
currently being studied in a Phase 1/2 clinical trial to treat
patients with CD19-positive adult acute lymphoblastic leukemia
(aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contact:
Carl MauchDirector, Investor Relations and
Corporate CommunicationsTCR2 Therapeutics Inc.(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Apr 2024 to May 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From May 2023 to May 2024